Category: Journal

Posted on

jhc.2024.8.1.08

Journal of Histopathology and Cytopathology

January 2024 Volume 8 Issue 1

Original Contribution

Evaluation of PD-L1 Immunoexpression  in Resected Samples of Colorectal Adenocarcinoma: A Study on 64 Cases

1. *Dr. Israt Jahan, Lecturer, Department of Pathology, Chandpur Medical College, Chandpur, Bangladesh; isratliza424@gmail.com
2. Dr. Bishnu Pada Dey, Associate Professor, Department of Pathology, BSMMU, drbishnu@bsmmu.edu.bd
3. Dr. Md. Akhtaruzzaman, Lecturer, Department of Pathology, Pabna Medical College, Pabna, Bangladesh; akter22nd@gmail.com
4. Dr. Kassim Hagi Hussain, Senior lecturer, Department of pathology, Jazeera University Medical College, Somalia; doctorqaasim@gmail.com
5. Dr. Mahabub Alam, Assisstant Professor, Department of Pathology, Bashundhara Ad-din Medical College & Hospital, Dhaka, Bangladesh; mahabub.robin@gmail.com
6. Dr. Md Zillur Rahman, Professor, Department of Pathology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Shahbagh, Dhaka-1000, Bangladesh;drzillur@bsmmu.edu.bd

*For correspondence

Abstract
Background: Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide and its incidence is rising steadily in developing nations. The patient prognosis for CRC remains poor, despite advances in surgery and treatment. Additionally, there are currently no reliable prognostic approaches for CRC, despite the use of conventional prognostic factors. Immune checkpoints blockades (ICB) have emerged as a promising treatment strategy and have dramatically improved long-term survival in several malignances. The “PD-1 (programmed cell death-1)”/PD-L1 (programmed cell death-ligand 1) axis plays an important role to control immune suppression by down-regulating T effector cell activities enable tumor cells to escape from the host’s anti-tumor immune surveillance. Aim of this study was to evaluate the expression of PD-L1 (28-8 clone) in resected samples of colorectal cancer.
Methods: This was a cross-sectional observational study. A total 64 cases were selected from the patients who were diagnosed as adenocarcinoma from resected samples received in the department of pathology at BSMMU from July 2021 to June 2023. Immuno-histochemical staining for PD-L1 was performed along with appropriate positive control.
Results: In this study PD-L1 immuno-expression was found in 14 (21.9%) out of 64 cases. However, no expression was found in rest of the 50 (78.1%) cases.
Conclusion: Evaluation of expression of PD-L1 may emerge as a new marker and target for the immunotherapy of colorectal cancer.

[Journal of Histopathology and Cytopathology, 2024 Jan; 8 (1):56-64]
DOI: https://www.doi.org/10.69950/jhc.2024.v8.i1.08
Keywords: CRC, ICB, PD-1, PD-L1, IRS.

Download Full

Posted on

jhc.2024.8.1.07

Journal of Histopathology and Cytopathology

January 2024 Volume 8 Issue 1

Original Contribution

Cyclin D1 Expression in Different Grades of Oral Squamous Cell Carcinoma: A Study Based on Small Biopsy Samples

1. *Dr. Abu Saeed Bin Hasem, MBBS, MD (Pathology), Lecturer, Department of Pathology, Sylhet MAG Osmani Medical College. saeedbinhasem@gmail.com.
2. Professor (Dr.) Azizul Qadar Md. Abdul Hye, M. Phil (Pathology), Former-Head and Professor, Department of Pathology, Sylhet MAG Osmani Medical College.
3. Professor (Dr.) Shamim Akhter Mimi, M. Phil (Pathology), Head and Professor, Department of Pathology, Sylhet MAG Osmani Medical College.
4. Dr. Md. Mizanur Rahman, MBBS, MD (Pathology), Assistant Professor, Pabna Medical College, Pabna.
5. Dr. Md. Shahrior Nahid, MBBS, MD (Pathology), Resident Medical Officer, National Institute of Laboratory Medicine and Referral Centre, Sher-e-Bangla Nagar, Agargaon, Dhaka-1207.
6. Dr. Umama-Tun-Nesa Emita, MBBS, MD (Pathology), Pathologist, Khulna Medical College Hospital, Khulna.
7. Dr. Sadia Afroz, MBBS, MD (Pathology), Medical Officer, Department of Histopathology, National Institute of Cancer Research and Hospital, Mohakhali, Dhaka-1212.

* For correspondence

Abstract
Background: Cyclin D1 oncogene plays a critical role in various malignancies by regulating the G1/S transition of the cell cycle. Overexpression of cyclin D1 in oral squamous cell carcinoma is associated with poor prognosis and resistance to cisplatin-based conventional chemotherapy.

Objectives:To assess the immunohistochemical expression of cyclin D1 in different grades of oral squamous cell carcinoma (OSCC) and to determine the association of cyclin D1 expression with histopathological grades, age, gender, anatomic site, and the habit of using tobacco, betel quid and areca nut of OSCC patients.
Methods: This cross-sectional observational study was conducted at the Department of Pathology, Sylhet MAG Osmani Medical College, Sylhet during the study period (from March, 2019 to April, 2020 and July, 2021 to April, 2022). A total of 52 small biopsy cases were processed; paraffin blocks were made and stained with routine H&E stain. The sections were examined microscopically and the tumors were graded histologically. Immunohistochemistry was performed by using a commercially available anti-cyclin D1 antibody. Cyclin D1 overexpression was considered when more than 10% of tumor cells displayed nuclear staining with moderate to strong intensity.
Results: Cyclin D1 overexpression was seen in 60% of cases of OSCC. The highest expression was seen in moderately differentiated followed by poorly differentiated and well-differentiated squamous cell carcinoma, with no statistically significant correlation. It did not correlate with age, gender, anatomic site, the habit of using tobacco, betel quid, and areca nut chewing.
Conclusion: In Bangladesh, 60% of cases of OSCC showed cyclin D1 overexpression which was quite similar to the findings of other countries. Further, alarge cohort study on resected samples can be done for overall survival and future targeted therapy against cyclin D1.

[Journal of Histopathology and Cytopathology, 2024 Jan; 8 (1):49-55]
DOI: https://www.doi.org/10.69950/jhc.2024.v8.i1.07
Keywords: Cyclin D1, Expression, OSCC, Overexpression

Download Full

Posted on

jhc.2024.8.1.04

Journal of Histopathology and Cytopathology

 January 2024 Volume 8 Issue 1

Original Contribution

Immunoexpression of WT1 in Astrocytoma and its Correlation with Histopathological Grade

1. *Dr. Evana Kabir, Specialist (Pathology), United Hospital Limited, Gulshan-2, Dhaka, Bangladesh; evana19901@gmail.com
2. Professor Dr. Md Rezaul Karim Dewan, Professor, Department of Pathology, Greenlife Medical College, Ex-Professor and head, Dhaka Medical College.
3. Dr. Rejwana Nahar, Assistant Professor, Department of Pathology, Mugda Medical college, Dhaka.
4. Dr. Sadia Afroz, Medical Officer, Department of Histopathology, National Institute of Cancer Research & Hospital (NICRH), Mohakhali, Dhaka-1212, Bangladesh.
5. Dr. Shamim Rahman, Assistant Professor, Department of Pathology, Jahurul Islam Medical College, Bajitpur Bangladesh.
6. Dr. Tasmia Islam, Specialist (Pathology), Square Hospital Limited, Sher-e-Bangla Nagar, Dhaka-1205, Bangladesh.
7. Dr. Khondoker Rakibul Hoque, Senior House Officer, Department of Orthopaedics, United Hospital Limited, Gulshan, Dhaka.

*For correspondence.
Abstract
Background:  Astrocytoma comprises a group of neoplasms that differ in their location in the Central nervous system, morphologic features and invasive behavior. These are therapeutically challenging for their infiltrative growth pattern, occasionally resistant to conventional therapies and invariably high grade tumors have shown poor prognosis. Moreover biological behavior of astrocytoma and chance of recurrence cannot be ruled out by histopathological evaluation alone. So, new predictive marker for determining tumor progression is at stake.
Objectives: The purpose of the study was to evaluate WT1 expression in astrocytoma and its correlation with histological grade.
Methods:  The cross-sectional observational study was conducted in the Department of Pathology, Dhaka Medical College (DMC) from September 2019 to August 2021. Histologically diagnosed 51 cases of different grades of astrocytoma were included in this study. Immunostaining with WT1 protein was done in all cases. The data were collected and statistical analysis was done by SPSS.
Results: The mean age for grade I, II, III and IV astrocytoma’s are 14, 27.5, 38.6 and 44 years respectively. There were 30 male and 21 female patients with the ratio 1.42:1. Among 51 cases of astrocytoma’s Grade I, II ,III and IV are 10, 15, 8 and 18 in number. By Immunohistochemical study positive WT1 expression was seen in all cases of astrocytoma’s (100%). Out of 25 cases of low grade astrocytoma’s (WHO grade I and II), expression was found mild in 12 (48%) cases, moderate in 11 (54%) cases and marked only 02 (8%) cases. Regarding 26 cases of high grade astrocytoma’s (WHO grade III and IV) expression found mostly marked in 16 (61.5%) cases, moderate in 09 (34.7%) and mild only in 01 (3.8%) cases. These data shows WT1 expression increases with WHO tumor grades and significant positive (p<0.001) correlation between WT1 expression and tumor grade.
Conclusion: The study reveals positive correlation between WT1 expressions with WHO tumor grade in astrocytoma. Furthermore, evaluation of WT1 with histopathological grading may provide information about tumor progression as well as guide the clinicians for therapeutic purposes.

[Journal of Histopathology and Cytopathology, 2024 Jan; 8 (1):19-30]

DOI: https://www.doi.org/10.69950/jhc.2024.v8.i1.04
Keywords: Astrocytoma, tumor grade, WT1 expression, tumor progression, Glioblastoma

Download Full